Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9666409 | 1.00 | KCNH2 (0.50) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9668318 | 1.00 | KCNH2 (0.50) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9705718 | 1.00 | KCNH2 (0.50) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9666126 | 0.99 | KCNH2 (0.51) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9862871 | 0.94 | HRH3 (0.46) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9705927 | 0.94 | HRH3 (0.46) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9862900 | 0.89 | KCNH2 (0.47) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9863086 | 0.89 | KCNH2 (0.48) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9668199 | 0.88 | KCNH2 (0.38) | KCNH2HRH3LTA4HCYP1A2CYP19A1 | |
| SCHEMBL9668491 | 0.88 | KCNH2 (0.38) | KCNH2HRH3LTA4HCYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2025235664-A1 | PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2025-09-11 | — | — | US | claimed |
| CN-120044159-A | Polygonatum sibiricum medicinal material species identification method based on polygonatum sibiricum characteristic compound and application | 河北北方学院 | 2025-05-27 | — | — | CN | claimed |
| WO-2024233354-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4333859-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | Emory University (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | claimed |
| WO-2003030934-A2 | CPG FORMULATIONS AND RELATED METHODS | MERIAL LIMITED (US) | 2003-04-17 | — | — | WO | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
| CN-1053101-C | Heterovesicular liposomes | SKY MEDICAMENTS CO LTD (US) | 2000-06-07 | — | — | CN | claimed |
| EP-0137242-B1 | (SUBSTITUTED) PHENYL-ALIPHATIC-ISOXAZOLES USEFUL AS ANTIVIRAL AGENTS AND PREPARATION THEREOF | STERLING WINTHROP INC. (US) | 1992-05-13 | — | — | EP | claimed |
| US-4956351-A | INCLUSION COMPLEXESOFVIRICIDES; RHINITIS; SUSTAINED RELEASE; NONIRRITATING TO MUCOUS MEMBRANE | JANSSEN PHARMACEUTICA N.V. FRAME-543 (BE) | 1990-09-11 | — | — | US | claimed |
| US-4843087-A | OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES | STERLING DRUG INC. (US) | 1989-06-27 | — | — | US | claimed |
| EP-0137242-A2 | (Substituted) Phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof | STERLING WINTHROP INC. (US) | 1985-04-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | NTPCR, TYMP, MTAP | KCNH2 4762/4885HRH3 4380/4885LTA4H 1385/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | KCNH2 1015/4885HRH3 2290/4885LTA4H 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.